GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Shiller PE Ratio

Osiris Therapeutics (Osiris Therapeutics) Shiller PE Ratio : 271.29 (As of May. 05, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Shiller PE Ratio?

As of today (2024-05-05), Osiris Therapeutics's current share price is $18.99. Osiris Therapeutics's E10 for the quarter that ended in Dec. 2018 was $0.07. Osiris Therapeutics's Shiller PE Ratio for today is 271.29.

The historical rank and industry rank for Osiris Therapeutics's Shiller PE Ratio or its related term are showing as below:

OSIR's Shiller PE Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 34.93
* Ranked among companies with meaningful Shiller PE Ratio only.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Osiris Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2018 was $0.940. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.07 for the trailing ten years ended in Dec. 2018.

Shiller PE for Stocks: The True Measure of Stock Valuation


Osiris Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Osiris Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Shiller PE Ratio Chart

Osiris Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 195.98

Osiris Therapeutics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 195.98

Competitive Comparison of Osiris Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Osiris Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Osiris Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Osiris Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Osiris Therapeutics's Shiller PE Ratio falls into.



Osiris Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Osiris Therapeutics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=18.99/0.07
=271.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Osiris Therapeutics's E10 for the quarter that ended in Dec. 2018 is calculated as:

For example, Osiris Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2018 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2018 (Change)*Current CPI (Dec. 2018)
=0.94/105.9979*105.9979
=0.940

Current CPI (Dec. 2018) = 105.9979.

Osiris Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200806 -0.480 92.320 -0.551
200809 0.170 92.307 0.195
200812 -0.240 88.697 -0.287
200903 0.450 89.744 0.532
200906 -0.300 91.003 -0.349
200909 -0.190 91.120 -0.221
200912 0.480 91.111 0.558
201003 0.070 91.821 0.081
201006 0.050 91.962 0.058
201009 0.140 92.162 0.161
201012 0.130 92.474 0.149
201103 0.120 94.283 0.135
201106 0.050 95.235 0.056
201109 0.120 95.727 0.133
201112 0.150 95.213 0.167
201203 -0.040 96.783 -0.044
201206 -0.130 96.819 -0.142
201209 -0.090 97.633 -0.098
201212 -0.080 96.871 -0.088
201303 -0.080 98.209 -0.086
201306 -0.120 98.518 -0.129
201309 -0.050 98.790 -0.054
201312 1.440 98.326 1.552
201403 -0.040 99.695 -0.043
201406 -0.050 100.560 -0.053
201409 0.020 100.428 0.021
201412 0.020 99.070 0.021
201503 0.040 99.621 0.043
201506 0.030 100.684 0.032
201509 -0.020 100.392 -0.021
201512 -1.060 99.792 -1.126
201612 -0.110 101.863 -0.114
201703 -0.050 102.862 -0.052
201706 0.020 103.349 0.021
201709 0.220 104.136 0.224
201712 0.050 104.011 0.051
201803 -0.070 105.290 -0.070
201806 0.070 106.317 0.070
201809 0.120 106.507 0.119
201812 0.940 105.998 0.940

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Osiris Therapeutics  (NAS:OSIR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Osiris Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Osiris Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Osiris Therapeutics (Osiris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707
Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.
Executives
Reinhart Charles A. Iii director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang officer: Chief Financial Officer ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal officer: Chiel Legal Officer
Linda Palczuk officer: President & CEO 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White director
Thomas J Knapp director 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr officer: Principal Accounting Officer
C Randal Mills director, officer: President & CEO 18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes director
Stephen W Potter officer: Senior Vice President 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill director

Osiris Therapeutics (Osiris Therapeutics) Headlines

From GuruFocus